Trial · NCT00736645
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
NCT00736645, Phase 2, Completed, Roswell Park Cancer Institute; results first posted 2017-11-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer. Trials, record NCT00736645. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00736645
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
- NCT number
- NCT00736645
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Roswell Park Cancer Institute
- Conditions
- Prostate Cancer
- Interventions
- selenomethionine, finasteride, placebo
- First posted
- 2008-08-18
- Last updated
- 2023-10-02
- Results first posted
- 2017-11-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effects of Selenium and Finasteride and Their Combination on PSA Level | 1 year | Compare PSA levels with Finasteride Placebo + Selenium Placebo group (Arm C). The Wilcoxon Rank Sum Test was used to test the difference of PSA levels of Arm A, Arm B, Arm D with Arm C. |
| Secondary | Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction | 1 year | Compare cleaved caspase 3 values with Finasteride Placebo + Selenium Placebo group (Arm C). The Wilcoxon Rank Sum Test was used to test the difference of cleaved caspase 3 values of Arm A, Arm B, Arm D with Arm C. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Effects of Selenium and Finasteride and Their Combination on PSA Level | 1 year | All treated and eligible patients | ng/mL | MEDIAN |
| SECONDARY | Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction | 1 year | All treated and eligible patients | percentage of apoptotic cells | MEDIAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Effects of Selenium and Finasteride and Their Combination on PSA Level | Arm A: Finasteride + Selenium Placebo | 1.9 | Full Range 0.8 to 2.6 | ng/mL | |
| Effects of Selenium and Finasteride and Their Combination on PSA Level | Arm B: Finasteride + Selenium | 1.9 | Full Range 1.7 to 2.2 | ng/mL | |
| Effects of Selenium and Finasteride and Their Combination on PSA Level | Arm C: Finasteride Placebo + Selenium Placebo | 2.0 | Full Range 1.4 to 2.7 | ng/mL | |
| Effects of Selenium and Finasteride and Their Combination on PSA Level | Arm D: Finasteride Placebo + Selenium | 2.1 | Full Range 1.3 to 2.7 | ng/mL | |
| Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction | Arm A: Finasteride + Selenium Placebo | 0.1 | Full Range 0 to 11.1 | percentage of apoptotic cells | |
| Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction | Arm B: Finasteride + Selenium | 0 | Full Range 0 to 0.7 | percentage of apoptotic cells | |
| Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction | Arm C: Finasteride Placebo + Selenium Placebo | 0 | Full Range 0 to 0.4 | percentage of apoptotic cells | |
| Effects of Selenium and Finasteride and Their Combination on Apoptosis Induction | Arm D: Finasteride Placebo + Selenium | 0 | Full Range 0 to 0.7 | percentage of apoptotic cells |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Finasteride + Selenium Placebo | 13 | |
| Overall Study | STARTED | Arm B: Finasteride + Selenium | 15 | |
| Overall Study | STARTED | Arm C: Finasteride Placebo + Selenium Placebo | 14 | |
| Overall Study | STARTED | Arm D: Finasteride Placebo + Selenium | 13 | |
| Overall Study | COMPLETED | Arm A: Finasteride + Selenium Placebo | 13 | |
| Overall Study | COMPLETED | Arm B: Finasteride + Selenium | 13 | |
| Overall Study | COMPLETED | Arm C: Finasteride Placebo + Selenium Placebo | 14 | |
| Overall Study | COMPLETED | Arm D: Finasteride Placebo + Selenium | 13 | |
| Overall Study | NOT COMPLETED | Arm A: Finasteride + Selenium Placebo | 0 | |
| Overall Study | NOT COMPLETED | Arm B: Finasteride + Selenium | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Arm A: Finasteride + Selenium Placebo | 1 | 13 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Arm B: Finasteride + Selenium | 0 | 15 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Arm C: Finasteride Placebo + Selenium Placebo | 0 | 14 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Arm D: Finasteride Placebo + Selenium | 0 | 13 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Arm A: Finasteride + Selenium Placebo | 0 | 13 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Arm B: Finasteride + Selenium | 0 | 15 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Arm C: Finasteride Placebo + Selenium Placebo | 1 | 14 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Arm D: Finasteride Placebo + Selenium | 0 | 13 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Arm A: Finasteride + Selenium Placebo | 1 | 13 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | Arm B: Finasteride + Selenium | 0 | 15 | 0 |
1 to 10 of 96Source ClinicalTrials.gov
See all 96 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: Finasteride + Selenium Placebo | ||
| Total, all-cause mortality | Arm B: Finasteride + Selenium | ||
| Total, all-cause mortality | Arm C: Finasteride Placebo + Selenium Placebo | ||
| Total, all-cause mortality | Arm D: Finasteride Placebo + Selenium | ||
| Total, other adverse events | Arm A: Finasteride + Selenium Placebo | 2 | 13 |
| Total, other adverse events | Arm B: Finasteride + Selenium | 3 | 15 |
| Total, other adverse events | Arm C: Finasteride Placebo + Selenium Placebo | 4 | 14 |
| Total, other adverse events | Arm D: Finasteride Placebo + Selenium | 3 | 13 |
| Total, serious adverse events | Arm A: Finasteride + Selenium Placebo | 0 | 13 |
| Total, serious adverse events | Arm B: Finasteride + Selenium | 2 | 15 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00736645
GET https://conductscience.org/api/trials/v1/NCT00736645/events?page=2